

A Reductive Alkylation Procedure Applicable to Both Solution- and Solid-Phase Syntheses of Secondary Amines

Anna K. Szardenings, Timothy S. Burkoth,
Gary C. Look, and David A. Campbell*

Affymax Research Institute, 4001 Miranda Avenue,
Palo Alto, California 94304

Received January 19, 1996 (Revised Manuscript Received June 19, 1996)

Introduction

The emergence of combinatorial library screening strategies for drug discovery has spurred intense activity in the field of solid-phase synthesis.¹ The ability to automate solid-phase syntheses, coupled with hyperentropic utility, the use of excess soluble reagents to drive reactions to completion, and the ready purification of resin-bound material² combine to make solid-phase synthesis the method of choice for combinatorial library generation. Secondary amines are important pharmacophores in many biologically active substances. Consequently, the monoalkylation of a primary amino group is an important transformation in organic synthetic chemistry. Secondary amines are typically synthesized via reductive alkylation of a primary amine with an aldehyde or ketone in the presence of a reducing agent (e.g., NaCNBH₃); however, overalkylation readily occurs and is of major concern.³ Solution-phase strategies circumvent overalkylation by using less than 1 equiv of the carbonyl component relative to amine. However, this strategy is not ideal for reductive alkylation of a resin-bound amine since it necessarily results in less than quantitative yields of the desired secondary amine.

A number of solid-phase reductive alkylation protocols have been described in the literature (NaCNBH₃ in 1% HOAc/DMF or NaHB(OAc)₃).⁴ In our hands, overalkylation to the tertiary amine was routinely observed when sterically undemanding aldehydes were used with these methods.⁵ We have recently reported the facile formation of imines on a solid support using trimethyl orthoformate (TMOF) as the solvent.⁶ In this paper, we describe a reductive alkylation procedure that provides high yields of secondary amines utilizing a large excess of carbonyl component and reducing agent in TMOF that is applicable to both solution- and solid-phase syntheses.

Results and Discussion


Reductive alkylations were initially studied in solution using phenylalaninamide as the amine component and

Table 1. Secondary Amine Synthesis via Reductive Alkylations of Primary Amines with Aldehydes and Ketones

no.	amine 1	carbonyl 2	isolated yield (%)
3a	H-Phe-NH ₂ :	propionaldehyde	77 ^a
3b	R ₁ = CH ₂ (C ₆ H ₅)	isobutyraldehyde	69
3c		trimethylacetaldehyde	80
3d		benzaldehyde	74
3e		acetone	82
3f		cyclohexanone	83
3g	H-Val-NH ₂ :	trimethylacetaldehyde	82 ^a
	R ₁ = CH(CH ₃) ₂		
3h	H-Phe-Phe-[resin]	propionaldehyde	61
3i		isobutyraldehyde	84 ^b
3j		benzaldehyde	75
3k	H-Val-Phe-[resin]	trimethylacetaldehyde	72 ^b

^aYield after standard aqueous workup. ^bYield after HPLC purification.

a variety of aldehydes representing a range of steric and electronic characteristics (Table 1).



Reductive alkylation with a large excess of propionaldehyde (10 equiv) and NaCNBH₃ (15 equiv) in neat TMOF yielded *N*-propyl-L-phenylalaninamide (**3a**) in 77% isolated yield with no evidence of overalkylated material observed by HPLC or mass spectral analysis. With the sterically hindered aldehydes isobutyraldehyde and trimethylacetaldehyde, identical conditions yielded a mixture of starting material and monoalkylated product. A dramatic improvement in isolated yields was obtained when the imine was preformed by combining phenylalaninamide and aldehyde for 30 min prior to addition of NaCNBH₃ (69% for isobutyraldehyde **3b** and 80% for trimethylacetaldehyde **3c**). Reductive alkylation of sterically demanding amines with bulky aliphatic aldehydes can also be achieved using these conditions as evidenced by the 82% yield obtained when valinamide was alkylated with trimethylacetaldehyde **3g**.

Attempts to alkylate phenylalaninamide with benzaldehyde yielded only starting material after workup even when imine formation was completed before addition of NaCNBH₃. Rationalizing that the benzylimine intermediate was too stable to be reduced under these conditions, the reaction was repeated in the presence of 1% HOAc to generate an iminium ion, which should be readily reduced. This was indeed the case, and *N*-benzyl-L-phenylalaninamide (**3d**) was obtained under these conditions with an isolated yield of 74%. This procedure has been successfully extended to the alkylation of phenylalaninamide with simple ketones in high yields (**3e** from acetone 82%; **3f** from cyclohexanone 83%).

In general, solution-phase reductive alkylations may be divided into three general classes. Unhindered aliphatic aldehydes simply require NaCNBH₃ in TMOF; hindered aliphatic aldehydes require premixing of the amine and aldehyde in TMOF followed by NaCNBH₃ addition; and aromatic aldehydes require premixing with the amine component followed by NaCNBH₃ addition in the presence of 1% HOAc. Experimentally, this is reduced to two procedures as hindered and unhindered aliphatic aldehydes may be treated identically.

* To whom correspondence should be addressed.

(1) (a) Gallop, M. A.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gordon, E. M. *J. Med. Chem.* **1994**, *37*, 1233. (b) Gordon, E. M.; Barrett, R. W.; Dower, W. J.; Fodor, S. P.; Gallop, M. A. *J. Med. Chem.* **1994**, *37*, 1385.

(2) Crowley, J. I.; Rapoport, H. *Acc. Chem. Res.* **1976**, *9*, 135 and references therein.


(3) Borch, R. F.; Bernstein, M. D.; Durst, H. D. *J. Am. Chem. Soc.* **1971**, *93*, 2897.

(4) (a) Ho, P. T.; Chang, D.; Zhong, J. W. X.; Musso, G. F. *Peptide Res.* **1993**, *6*, 10. (b) Coy, D. H.; Hocart, S. J.; Sasaki, Y. *Tetrahedron* **1988**, *44*, 835. (c) Gordon, D. W.; Steele, J. *Biorg. Med. Chem. Lett.* **1995**, *5*, 47.

(5) Similar observations have recently been reported during the reductive alkylation of glycine derivatives with Fmoc-amino aldehydes: Salvi, J. P.; Walchshofer, N.; Paris, J. *Tetrahedron Lett.* **1994**, *35*, 1181.

(6) Look, G. C.; Murphy, M. M.; Campbell, D. A.; Gallop, M. A. *Tetrahedron Lett.* **1995**, *36*, 2937.

Scheme 1



We next investigated the reductive alkylation on a solid support using amino acid dimers containing phenylalanine at the carboxy terminus (Scheme 1).

Alkylation of Phe-Phe dimer with propionaldehyde in neat TMOF yielded, upon cleavage and HPLC purification, 61% of the *N*-propyl dimer **3h**. Reductive alkylations with isobutyraldehyde were incomplete even when prolonged imine formation time intervals were used, in contrast to the results obtained in solution (see **3b**), while addition of HOAc to the reaction mixture resulted in overalkylation. This problem was overcome by adding 1% MeOH as the proton source to the reductive alkylation mixture, yielding the desired *N*-isobutyl dimer **3i** in 84% yield. Similar to the solution-phase reaction, alkylation with benzaldehyde required 1% HOAc and yielded 75% of the *N*-benzyl dimer **3j**. Attempted monoalkylation of the Gly-Phe dimer with alkyl aldehydes was unsuccessful, yielding a mixture of secondary and tertiary amines. Reductive alkylation of the sterically demanding Val-Phe dimer with bulky trimethylacetaldehyde in 1% HOAc yielded the *N*-neopentyl-Val-Phe dimer **3k** in 72% yield. Thus, solution phase conditions could be extended to the solid phase with the difference that for hindered aliphatic aldehydes, premixing as well as a mild proton source (i.e., MeOH) are required.

The successful monoalkylation of primary amino groups obtained using this procedure may be attributed to the fact that the reductive potential of imines can be attenuated by varying the proton source present during the reduction with NaCNBH₃. This is possible because imine formation occurs in TMOF irrespective of the presence of an acid catalyst. Depending upon the steric encumbrance or electronics of the imine, the reductive potential can be attenuated by using either MeOH or HOAc as the exogenous proton source. With the procedures described in the literature,⁴ manipulation of an imine's reactivity by varying the proton source was unsuccessful presumably because HOAc is required to catalyze imine formation as well as to generate an iminium ion.

In summary, we have described methodology that enables the monoalkylation of amines with various aldehydes and ketones covering a wide range of steric and electronic characteristics. The procedure has been shown to work in both solution and on a solid support. This procedure should find broad application in syntheses requiring the formation of secondary amines. Application of this work to the generation of various synthetic combinatorial libraries is ongoing and will be reported in due course.

Experimental Section

General Procedures. Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. PAL-TM support (for peptide amides) was purchased from Millipore. ¹H-NMR spectra were determined at 400 MHz and ¹³C-NMR at 101 MHz. Mass spectral data were obtained by electrospray mass spectroscopy. Elemental analyses were performed at the University of California, Berkeley, CA.

***N*-Propyl-L-phenylalaninamide·TsOH (3a).** To phenylalaninamide (0.250 g, 1.52 mmol) dissolved in trimethyl orthoformate (20 mL) under argon was added propionaldehyde (1.1 mL, 15.2 mmol) followed by NaCNBH₃ (0.478 g, 7.61 mmol) dissolved in trimethyl orthoformate (20 mL). After 1 h the reaction mixture was cooled to 0 °C, quenched with 2% aqueous HCl (50 mL), and washed with ether (25 mL × 3). The ether phase was extracted with 2% aqueous HCl (25 mL × 2), and the aqueous phases were combined, cooled to 0 °C, treated with concentrated NaOH until basic, and then extracted with ether (25 mL × 4). The ether phase was dried over MgSO₄ and filtered. The filtrate was treated with *p*-toluenesulfonic acid (1.672 mmol) dissolved in ether (10 mL) and then placed in the freezer. The precipitate was collected by vacuum filtration, washed with ether, and dried under vacuum to provide **3a** as a colorless solid (0.441 g, 77%). ¹H-NMR (CD₃OD) δ: 7.72 (d, *J* = 8 Hz, 2H), 7.28 (m, 7H), 4.07 (m, 1H), 3.22 (m, 1H), 3.10 (m, 1H), 2.91 (m, 2H), 2.37 (s, 3H), 1.73 (m, 2H), 0.97 (t, *J* = 7 Hz, 3H). ¹³C-NMR (CD₃OD) δ: 170.8, 143.6, 141.9, 135.6, 130.7, 130.1, 128.9, 127.1, 62.9, 49.7, 37.9, 21.5, 20.8, 11.3. MS (MH⁺, *m/z*): 206. Anal. Calcd for C₁₉H₂₆N₂O₄S·0.2H₂O: C, 59.71; H, 6.98; N, 7.33. Found: C, 59.31; H, 6.96; N, 7.42.

***N*-Isobutyl-L-phenylalaninamide·TsOH (3b).** To phenylalaninamide (0.255 g, 1.55 mmol) dissolved in trimethyl orthoformate (20 mL) under argon was added isobutyraldehyde (1.4 mL, 15.4 mmol) followed by NaCNBH₃ (0.487 g, 7.75 mmol) dissolved in trimethyl orthoformate (20 mL). After 1 h, the reaction was worked up as described above for **3a** to yield **3b** as a colorless solid (0.420 g, 69%). ¹H-NMR (CD₃OD) δ: 7.72 (d, *J* = 8 Hz, 2H), 7.28 (m, 7H), 4.16 (m, 1H), 3.37 (m, 1H), 3.21 (m, 1H), 2.97 (m, 1H), 2.81 (m, 1H), 2.47 (s, 3H), 2.11 (m, 1H), 1.12 (t, *J* = 7 Hz). ¹³C-NMR (CD₃OD) δ: 170.7, 143.6, 141.9, 135.6, 130.7, 130.1, 130.0, 128.9, 127.1, 63.5, 55.4, 37.7, 27.4, 21.4, 20.6, 20.3. MS (MH⁺, *m/z*): 221. Anal. Calcd for C₂₀H₂₈N₂O₄S·0.2H₂O: C, 60.63; H, 7.24; N, 7.07. Found: C, 60.32; H, 7.30; N, 7.20.

***N*-(2,2-Dimethylpropyl)-L-phenylalaninamide·TsOH (3c).** To phenylalaninamide (0.125 g, 761 μmol) dissolved in trimethyl orthoformate (10 mL) under argon was added trimethylacetaldehyde (0.83 mL, 7.64 mmol) followed by NaCNBH₃ (0.245 g, 3.89 mmol) dissolved in trimethyl orthoformate (10 mL). After 1 h, the reaction was worked up as described above for **3a** to yield **3c** as a colorless solid (0.249 g, 80%). ¹H-NMR (CD₃OD) δ: 7.72 (d, *J* = 8 Hz, 2H), 7.28 (m, 7H), 4.04 (m, 1H), 3.32 (m, 1H), 3.13 (m, 1H), 2.94 (1H), 2.68 (1H), 2.48 (s, 3H), 1.07 (s, 9H). ¹³C-NMR (CD₃OD) δ: 170.5, 143.6, 141.9, 135.8, 130.8, 130.1, 130.0, 128.8, 127.1, 64.3, 59.8, 37.5, 31.7, 27.5, 21.5. MS (MH⁺, *m/z*): 235. Anal. Calcd for C₂₁H₃₀N₂O₄S: C, 62.03; H, 7.45; N, 6.89. Found: C, 61.84; H, 7.70; N, 6.88.

***N*-Benzyl-L-phenylalaninamide·TsOH (3d).** To phenylalaninamide (0.259 g, 1.58 mmol) dissolved in trimethyl orthoformate (20 mL) under argon were added acetic acid (0.4 mL) and benzaldehyde (1.6 mL, 15.7 mmol). After 30 min NaCNBH₃ dissolved in trimethyl orthoformate (20 mL), was added. After 1 h the reaction was worked up as described for **3a** to yield **3d** as a colorless solid (0.501 g, 74%). ¹H-NMR (CD₃OD) δ: 7.72 (d, *J* = 8 Hz, 2H), 7.46 (m, 5H), 7.28 (m, 7H), 4.15 (s, 2H), 4.08 (m, 1H), 3.24 (m, 1H), 3.12 (m, 1H), 2.37 (s, 3H). ¹³C-NMR (CD₃OD) δ: 170.6, 143.6, 141.8, 135.5, 132.1, 131.0, 130.9, 130.7, 130.4, 130.1, 130.0, 128.9, 127.1, 62.5, 51.5, 37.8, 21.4. MS (MH⁺, *m/z*): 255. Anal. Calcd for C₂₃H₂₆N₂O₄S·0.3H₂O: C, 63.95; H, 6.22; N, 6.49. Found: C, 63.80; H, 6.15; N, 6.39.

***N*-Isopropyl-L-phenylalaninamide·TsOH (3e).** To phenylalaninamide (0.252 g, 1.53 mmol) dissolved in trimethyl orthoformate (20 mL) under argon was added acetic acid (0.4 mL) followed by acetone (1.1 mL, 15.0 mmol). After 30 min, NaCNBH₃ (0.482 g, 7.67 mmol) dissolved in trimethyl orthoformate (20 mL) was added. After 1 h, the reaction was worked

up as described above for **3a** to yield **3e** as a colorless solid (0.477 g, 82%). ¹H-NMR (CD₃OD) δ: 7.72 (d, *J* = 8 Hz, 2H), 7.28 (m, 7H), 4.11 (m, 1H), 3.36 (m, 1H), 3.20 (m, 1H), 3.09 (m, 1H), 2.37 (s, 3H), 1.35 (d, *J* = 5 Hz, 3H), 1.33 (d, *J* = 5 Hz, 3H). ¹³C-NMR (CD₃OD) δ: 166.7, 139.6, 137.8, 131.5, 126.7, 126.0, 125.9, 124.8, 123.1, 56.4, 47.3, 34.1, 17.4, 16.1, 14.8. MS (MH⁺, *m/z*): 207. Anal. Calcd for C₁₉H₂₆N₂O₄S·0.5H₂O: C, 58.88; H, 7.04; N, 7.23. Found: C, 58.68; H, 7.04; N, 7.15.

N-Cyclohexyl-L-phenylalaninamide-TsOH (3f). To phenylalaninamide (0.257 g, 1.56 mmol) dissolved in trimethyl orthoformate (20 mL) under argon were added acetic acid (0.4 mL) and cyclohexanone (1.6 mL, 15.4 mmol). After 30 min, NaCNBH₃ (0.492 g, 7.83 mmol) dissolved in trimethyl orthoformate (20 mL) was added. After 1 h, the reaction was worked up as described above for **3a** to yield **3f** as a colorless solid (0.540 g, 83%). ¹H-NMR (CD₃OD) δ: 7.71 (d, *J* = 8 Hz, 2H), 7.29 (m, 7H), 4.17 (m, 1H), 3.20 (m, 1H), 3.09 (m, 1H), 2.99 (m, 1H), 2.38 (s, 3H), 2.10 (m, 2H), 1.84 (m, 2H), 1.68 (m, 1H), 1.29 (m, 5H). ¹³C-NMR (CD₃OD) δ: 170.80, 141.87, 135.65, 130.71, 130.06, 129.98, 128.86, 127.10, 59.82, 57.97, 38.09, 31.10, 29.93, 26.08, 25.71, 21.46. MS (MH⁺, *m/z*): 247. Anal. Calcd for C₂₂H₃₀N₂O₄S·0.3H₂O: C, 62.32; H, 7.29; N, 6.61. Found: C, 61.99; H, 7.42; N, 6.46.

N-(2,2-Dimethylpropyl)-L-valinamide-TsOH (3g). To valinamide (0.120 g, 1.03 mmol) dissolved in trimethyl orthoformate (15 mL) under argon was added trimethyl acetaldehyde (1.1 mL, 10.1 mmol) followed by NaCNBH₃ (0.324 g, 5.16 mmol) dissolved in trimethyl orthoformate (15 mL). After 1 h, the reaction was worked up as described above for **3a** to yield **3g** as a colorless solid (0.304 g, 82%). ¹H-NMR (CD₃OD) δ: 7.71 (d, *J* = 8 Hz, 2H), 7.24 (d, *J* = 8 Hz, 2H), 3.71 (d, *J* = 5 Hz, 1H), 2.99 (m, 1H), 2.66 (m, 1H), 2.38 (s, 3H), 2.32 (m, 1H), 1.16 (d, *J* = 7 Hz, 3H), 1.07 (s, 9H), 1.05 (d, *J* = 7 Hz, 3H). ¹³C-NMR (CD₃OD) δ: 169.71, 143.66, 141.85, 129.96, 127.08, 68.79, 60.85, 31.76, 30.39, 27.48, 21.44, 20.35, 17.82. MS (MH⁺, *m/z*): 187. Anal. Calcd for C₁₇H₃₀N₂O₄S: C, 56.94; H, 8.45; N, 7.81. Found: C, 56.79; H, 8.60; N, 7.57.

N-Propyl-Phe-Phe-amide-TFA (3h). To H₂N-Phe-Phe on PAL resin (170 mg, 0.046 mmol) suspended in trimethyl orthoformate (2.0 mL) under argon was added propionaldehyde (74 μL, 1.03 mmol) and the mixture shaken for 30 min. NaCNBH₃ (64 mg, 1.03 mmol) dissolved in trimethyl orthoformate (1.0 mL) was added. After 10 min the resin was drained, washed with methanol and ether, and dried. The N-alkylated peptide was cleaved from the resin with 95% trifluoroacetic acid/water (3 mL) for 3 h and filtered and the resin washed with trifluoroacetic acid. After concentration of the filtrate the crude material was purified by preparative HPLC using a water/acetonitrile/trifluoroacetic acid gradient to yield **3h** as a colorless solid (13 mg, 61%). ¹H-NMR (CD₃OD) δ: 0.69 (t, *J* = 7.5 Hz, 3H), 1.34 (m, 2H), 1.69 (ddd, *J* = 6.3, 9.1, 11.8 Hz, 1H), 2.22 (ddd, *J* = 5.8, 9.2, 11.8 Hz, 1H), 2.51 (dd, *J* = 11.6, 14.0 Hz, 1H), 2.80 (dd, *J* = 10.8, 12.4 Hz, 1H), 3.07 (dd, *J* = 4.8, 12.6 Hz, 1H), 3.17 (dd, *J* =

4.1, 14.0 Hz, 1H), 3.82 (dd, *J* = 4.8, 10.8 Hz, 1H), 4.54 (dd, *J* = 4.1, 11.6 Hz, 1H), 7.09–7.31 (m, 10H). ¹³C-NMR (CD₃OD) δ: 11.3, 20.5, 23.7, 37.9, 39.2, 55.3, 62.9, 128.0, 129.0, 129.5, 130.1, 130.2, 130.3, 130.4, 135.1, 138.5, 167.7, 174.6. FAB HRMS: calcd for C₂₁H₂₈N₃O₂ (MH⁺) 354.2182, found 354.2189.

N-(2-Methylpropyl)-L-Phe-Phe-amide-TFA (3i). To H₂N-Phe-Phe on PAL resin (190 mg, 0.051 mmol) suspended in trimethyl orthoformate (2.0 mL) under argon was added isobutyraldehyde (94 μL, 1.03 mmol) and the mixture shaken for 30 min. NaCNBH₃ (64 mg, 1.03 mmol) dissolved in trimethyl orthoformate (1.0 mL) was added. After 10 min the reaction was worked up as described above for **3h** to yield **3i** as a colorless solid (21 mg, 84%). ¹H-NMR (CD₃OD) δ: 0.86 (d, *J* = 6.7 Hz, 3H), 0.89 (d, *J* = 6.7 Hz, 3H), 1.79 (m, 1H), 1.93 (dd, *J* = 7.8, 12.2 Hz, 1H), 2.42 (dd, *J* = 5.9, 12.2 Hz, 1H), 2.73 (dd, *J* = 12.1, 14.0 Hz, 1H), 3.13 (m, 3H), 3.89 (dd, *J* = 5.9, 9.4 Hz, 1H), 4.72 (dd, *J* = 4.6, 10.6 Hz, 1H), 7.18–7.35 (m, 10H). ¹³C-NMR (CD₃OD) δ: 20.1, 20.5, 27.3, 37.8, 39.2, 55.0, 55.5, 63.5, 128.1, 129.0, 129.6, 130.2, 130.4, 130.5, 135.2, 138.4, 167.8, 174.5. FAB HRMS: calcd for C₂₂H₃₀N₃O₂ (MH⁺) 368.2338, found 368.2340.

N-Benzyl-Phe-Phe-amide-TFA (3j). To H₂N-Phe-Phe on PAL resin (226 mg, 0.063 mmol) suspended in trimethyl orthoformate (2.0 mL) under argon was added benzaldehyde (65 μL, 0.63 mmol) and the mixture shaken for 30 min. NaCNBH₃ (40 mg, 0.63 mmol) dissolved in trimethyl orthoformate (1.0 mL) was added followed by acetic acid (30 μL). After 10 min the reaction was worked up as described above for **3h** to yield **3j** as a colorless solid (24 mg, 75%). ¹H-NMR (CD₃OD) δ: 2.74 (dd, *J* = 11.0, 14.0 Hz, 1H), 3.09 (m, 5H), 3.22 (dd, *J* = 9.5, 14.0 Hz, 1H), 3.30 (m, 1H), 3.55 (d, *J* = 12.7 Hz, 1H), 3.94 (dd, *J* = 6.0, 9.0 Hz, 1H), 6.98 (m, 1H), 7.44–7.01 (m, 14H). ¹³C-NMR (CD₃OD) δ: 37.7, 39.3, 51.2, 55.4, 62.8, 128.1, 129.0, 129.6, 130.1, 130.2, 130.4, 130.5, 130.8, 131.2, 131.8, 135.1, 138.5, 167.8, 174.6. FAB HRMS: calcd for C₂₅H₂₈N₃O₂ (MH⁺) 402.2182, found 402.2184.

N-(2,2-Dimethylpropyl)-Val-Phe-amide-TFA (3k). To H₂N-Val-Phe on PAL resin (304 mg, 0.09 mmol) suspended in trimethyl orthoformate (4.5 mL) under argon was added 2,2-dimethylpropionaldehyde (98 μL, 0.9 mmol) and the mixture shaken for 30 min. NaCNBH₃ (57 mg, 0.9 mmol) dissolved in trimethyl orthoformate (1.5 mL) was added followed by acetic acid (50 μL). After 10 min the reaction was worked up as described above for **3h** to yield **3k** as a colorless solid (29 mg, 72%). ¹H-NMR (CD₃OD) δ: 0.90 (s, 9H), 0.98 (d, *J* = 6.9 Hz, 3H), 1.13 (d, *J* = 6.9 Hz, 3H), 1.90 (d, *J* = 12.3 Hz, 1H), 2.21 (m, 1H), 2.60 (d, *J* = 12.3 Hz, 1H), 2.87 (dd, *J* = 11.3, 13.6 Hz, 1H), 3.20 (dd, *J* = 4.5, 11.3 Hz, 1H), 3.30 (m, 1H), 3.50 (m, 1H), 7.33–7.19 (m, 5H). ¹³C-NMR (CD₃OD) δ: 17.9, 20.2, 27.2, 31.1, 31.5, 39.5, 55.4, 60.5, 68.7, 128.1, 129.6, 130.4, 138.5, 166.8, 175.2. FAB HRMS calcd for C₁₉H₃₂N₃O₂ (MH⁺) 334.2494, found 334.2497.

JO960124N